Abstract
12 and throughout the study. No safety issues were reported. HCC developed in 5 non cirrhotics (2.4%) between month 19 and 46 of treatment, with an yearly rate of 0.5%. The 155 compensated cirrhotics remained clinically stable, yet 17 developed a HCC to give a 5-year cumulative rate of 14% and an yearly rate of 2.8%, despite full suppression of viral replication in most cases. Five cirrhotics died for non-liver related causes, 2 for HCC and 4 were transplanted for HCC: the overall 5-year cumulative survival and liver-related survival were 91% and 95%, respectively. Conclusion: Entecavir monotherapy efficiently suppressed HBV in naive patients with CHB, fully preventing clinical decompensation but not HCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
